Ono Pharmaceutical , Ltd. Overview
Latest ROE for Ono Pharmaceutical , Ltd.: 8.89% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow8.89%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Ono Pharmaceutical , Ltd. (OPHLF) currently reports a ROE of 8.89%. That is below the sector sector average of 11.64%. Use the charts on this page to explore Ono Pharmaceutical , Ltd.'s ROE history and peer comparisons.
Ono Pharmaceutical , Ltd.'s ROE of 8.89% is lower than the its sector sector average of 11.64%. That is roughly 23.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Ono Pharmaceutical , Ltd.'s current 8.89% should be judged against industry norms (sector average: 11.64%) and against OPHLF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 8.89%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.64%. From there, open related valuation or income-statement pages for Ono Pharmaceutical , Ltd., and consider following OPHLF for alerts when major investors trade the stock.
